Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF 84 Net Cash per Share is $0.49 as of Jun. 2026. GuruFocus rates SUSRF with a GF Score™ of 84/100 and a GF Value™ of $19.47 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 135 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 58.52% on this metric.
The historical rank and industry rank for Surgical Science Sweden AB's Net Cash per Share or its related term are showing as below:
SUSRF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.55 Med: 33.11 Max: 401.71
Current: 11.06
During the past 11 years, the highest Price-to-Net-Cash Ratio of Surgical Science Sweden AB was 401.71. The lowest was 5.55. And the median was 33.11.
SUSRF's Price-to-Net-Cash is ranked worse than 58.52% of 135
companies
in the Healthcare Providers & Services industry
Industry Median: 8.35
vs SUSRF: 11.06
Surgical Science Sweden AB (OTCPK:SUSRF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Surgical Science Sweden AB Net Cash per Share Related Terms
Surgical Science Sweden AB Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Net Cash per Share Chart
SUSRF vs VEEV, BTSG, HQY: Net Cash per Share Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Price-to-Net-Cash falls into.
Surgical Science Sweden AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Surgical Science Sweden AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Net Cash per Share of $0.49 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #79 out of 135 companies in the Healthcare Providers & Services industry, placing it in the top 58.5%.
Is Surgical Science Sweden AB's Net Cash per Share too high?
Surgical Science Sweden AB's current Net Cash per Share is $0.49. The Healthcare Providers & Services industry median Net Cash per Share is 8.35. Surgical Science Sweden AB's value of $0.49 is 94.1% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #79 out of 135 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Net Cash per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #79 out of 135 companies for Net Cash per Share. This places Surgical Science Sweden AB in the lower half of its industry. The industry median Net Cash per Share is 8.35. Surgical Science Sweden AB's value of $0.49 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 8.35, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Net Cash per Share of $0.49 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 8.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Net Cash per Share is $0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.47, compared to a current price of $5.20 — trading 73.3% below its estimated fair value. The current Net Cash per Share is $0.49 and 94.1% below the Healthcare Providers & Services industry median of 8.35. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Net Cash per Share is $0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $5.20 is trading 73.3% below its estimated GF Value™ of $19.47.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Net Cash per Share: $0.49
GF Value™: $19.47 vs. price of $5.20 (73.3% below fair value)
Industry Position: 94.1% below the Healthcare Providers & Services median (#79 of 135)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for SUSRF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
